免疫检查点阻断的肾脏并发症
Renal complications of immune checkpoint blockade.
作者信息
Murakami Naoka, Motwani Shveta, Riella Leonardo V
机构信息
Schuster Family Transplantation Research Center, Renal Division, Brigham and Women's Hospital, Boston, Massachusetts; Renal Division, Brigham and Women's Hospital, Boston, Massachusetts.
Renal Division, Brigham and Women's Hospital, Boston, Massachusetts; Adult Survivorship Program, Dana Farber Cancer Institute, Boston, Massachusetts.
出版信息
Curr Probl Cancer. 2017 Mar-Apr;41(2):100-110. doi: 10.1016/j.currproblcancer.2016.12.004. Epub 2016 Dec 19.
Abstract
Immune checkpoint inhibitors have been approved for a variety of cancer species. Renal complications in use of these agents are not very common compared with other immune-related adverse events (irAE). However, it is crucial for physicians to recognize and manage renal manifestations of irAE. In this review, we will summarize the up-to-date knowledge of the clinical presentation, pathologic features, and management of renal irAE. In addition, we will discuss the safety of immune checkpoint inhibitors in patients with chronic kidney disease as well as in kidney transplant recipients.
摘要
免疫检查点抑制剂已被批准用于多种癌症。与其他免疫相关不良事件（irAE）相比，使用这些药物时出现的肾脏并发症并不常见。然而，医生认识并处理irAE的肾脏表现至关重要。在本综述中，我们将总结irAE的临床表现、病理特征及处理方面的最新知识。此外，我们还将讨论免疫检查点抑制剂在慢性肾脏病患者以及肾移植受者中的安全性。
相似文献
1
Renal complications of immune checkpoint blockade.免疫检查点阻断的肾脏并发症
Curr Probl Cancer. 2017 Mar-Apr;41(2):100-110. doi: 10.1016/j.currproblcancer.2016.12.004. Epub 2016 Dec 19.
2
Cutaneous adverse effects of the immune checkpoint inhibitors.免疫检查点抑制剂的皮肤不良反应。
Curr Probl Cancer. 2017 Mar-Apr;41(2):125-128. doi: 10.1016/j.currproblcancer.2016.12.001. Epub 2016 Dec 14.
3
Management of toxicities of immune checkpoint inhibitors.免疫检查点抑制剂毒性的管理。
Cancer Treat Rev. 2016 Mar;44:51-60. doi: 10.1016/j.ctrv.2016.02.001. Epub 2016 Feb 6.
4
Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.分子途径：免疫检查点抗体及其毒性。
Clin Cancer Res. 2016 Sep 15;22(18):4550-5. doi: 10.1158/1078-0432.CCR-15-2569. Epub 2016 Jul 19.
5
Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies.与 PD-1 阻断抗体相关的炎症性胃肠道疾病。
Ann Oncol. 2017 Nov 1;28(11):2860-2865. doi: 10.1093/annonc/mdx403.
6
Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora?抗 CTLA-4 导致的炎症性肠病和癌症反应：是否与菌群有关？
Semin Immunopathol. 2017 Apr;39(3):327-331. doi: 10.1007/s00281-016-0613-x. Epub 2017 Jan 16.
7
Kidney Complications of Immune Checkpoint Inhibitors: A Review.免疫检查点抑制剂的肾脏并发症：综述。
Am J Kidney Dis. 2019 Oct;74(4):529-537. doi: 10.1053/j.ajkd.2019.03.433. Epub 2019 Jul 11.
8
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.免疫检查点阻断相关的免疫相关不良事件：一项全面综述。
Eur J Cancer. 2016 Feb;54:139-148. doi: 10.1016/j.ejca.2015.11.016. Epub 2016 Jan 5.
9
Immune checkpoint inhibitors renal side effects and management.免疫检查点抑制剂的肾脏副作用及管理
Immunotherapy. 2016 Dec;8(12):1417-1425. doi: 10.2217/imt-2016-0099.
10
[Adverse events of immune checkpoint inhibitors].[免疫检查点抑制剂的不良事件]
Urologe A. 2017 Apr;56(4):486-491. doi: 10.1007/s00120-017-0342-3.
引用本文的文献
1
IgG4-related disease with interstitial nephritis in a patient with metastatic melanoma following immune checkpoint inhibitor treatment: a case report.免疫检查点抑制剂治疗后转移性黑色素瘤患者并发IgG4相关性疾病伴间质性肾炎：一例报告
BMC Rheumatol. 2025 Aug 1;9(1):95. doi: 10.1186/s41927-025-00548-1.
2
Immune Checkpoint Inhibitors and Allograft Rejection Risk: Emerging Evidence Regarding Their Use in Kidney Transplant Recipients.免疫检查点抑制剂与同种异体移植排斥风险：关于其在肾移植受者中应用的新证据
J Clin Med. 2025 Jul 20;14(14):5152. doi: 10.3390/jcm14145152.
3
Immune checkpoint inhibitor therapy in metastatic renal cell carcinoma: tumour response and immune-related renal vasculitis following cytoreductive nephrectomy.转移性肾细胞癌的免疫检查点抑制剂治疗：减瘤性肾切除术后的肿瘤反应及免疫相关性肾血管炎
Pathologica. 2025 Jun;117(3):249-257. doi: 10.32074/1591-951X-N998. Epub 2025 Jun 6.
4
Characterization of renal injury in non-squamous non-small cell lung cancer patients treated with pemetrexed: A single-center retrospective study.培美曲塞治疗非鳞状非小细胞肺癌患者肾损伤的特征：一项单中心回顾性研究。
Thorac Cancer. 2024 Dec;15(35):2474-2485. doi: 10.1111/1759-7714.15470. Epub 2024 Oct 29.
5
Single-cell RNA sequencing analysis of peripheral blood mononuclear cells in PD-1-induced renal toxicity in patients with lung cancer.单细胞 RNA 测序分析肺癌患者 PD-1 诱导的肾毒性外周血单个核细胞。
BMC Nephrol. 2024 Sep 14;25(1):307. doi: 10.1186/s12882-024-03754-0.
6
Immune checkpoint inhibitors and acute kidney injury.免疫检查点抑制剂与急性肾损伤。
Front Immunol. 2024 Feb 23;15:1353339. doi: 10.3389/fimmu.2024.1353339. eCollection 2024.
7
Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature.免疫检查点抑制剂联合治疗导致的肾病综合征伴急性肾损伤：病例报告及文献复习。
BMC Nephrol. 2024 Feb 9;25(1):51. doi: 10.1186/s12882-024-03494-1.
8
Short-term steroid therapy for immune-checkpoint-inhibitor-related acute kidney injury.免疫检查点抑制剂相关急性肾损伤的短期类固醇治疗
Int Urol Nephrol. 2024 Mar;56(3):1199-1200. doi: 10.1007/s11255-023-03734-7. Epub 2023 Aug 30.
9
Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.免疫检查点抑制剂治疗的癌症患者发生急性肾损伤的发生率和风险因素：系统评价和荟萃分析。
Front Immunol. 2023 May 29;14:1173952. doi: 10.3389/fimmu.2023.1173952. eCollection 2023.
10
Safety of Immune Checkpoint Inhibitors in Patients With Advanced Chronic Kidney Disease: A Retrospective Cohort Study.免疫检查点抑制剂在晚期慢性肾脏病患者中的安全性：一项回顾性队列研究。
Oncologist. 2023 Jun 2;28(6):e379-e390. doi: 10.1093/oncolo/oyad001.
本文引用的文献
1
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient.慢性肾衰竭及器官移植受者中的检查点抑制剂
Eur J Cancer. 2016 Nov;67:66-72. doi: 10.1016/j.ejca.2016.07.026. Epub 2016 Sep 8.
2
Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient.心脏移植患者免疫检查点抑制癌症治疗的耐受性
Ann Oncol. 2016 Dec;27(12):2304-2305. doi: 10.1093/annonc/mdw293. Epub 2016 Aug 8.
3
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.纳武利尤单抗用于自体干细胞移植和维布妥昔单抗均治疗失败后的经典型霍奇金淋巴瘤：一项多中心、多队列、单臂2期试验。
Lancet Oncol. 2016 Sep;17(9):1283-94. doi: 10.1016/S1470-2045(16)30167-X. Epub 2016 Jul 20.
4
Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors: A Review.免疫检查点抑制剂相关不良反应的治疗：综述。
JAMA Oncol. 2016 Oct 1;2(10):1346-1353. doi: 10.1001/jamaoncol.2016.1051.
5
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.与免疫检查点抑制剂相关的急性肾损伤的临床病理特征
Kidney Int. 2016 Sep;90(3):638-47. doi: 10.1016/j.kint.2016.04.008. Epub 2016 Jun 7.
6
Severe acute interstitial nephritis after combination immune-checkpoint inhibitor therapy for metastatic melanoma.转移性黑色素瘤联合免疫检查点抑制剂治疗后发生的严重急性间质性肾炎。
Clin Kidney J. 2016 Jun;9(3):411-7. doi: 10.1093/ckj/sfw024. Epub 2016 May 4.
7
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.纳武利尤单抗和伊匹木单抗序贯给药并计划在晚期黑色素瘤患者中进行转换（CheckMate 064）：一项开放标签、随机、2期试验。
Lancet Oncol. 2016 Jul;17(7):943-955. doi: 10.1016/S1470-2045(16)30126-7. Epub 2016 Jun 4.
8
Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.抗 CTLA-4 和抗 PD-1 抗体单药及联合治疗的安全性特征。
Nat Rev Clin Oncol. 2016 Aug;13(8):473-86. doi: 10.1038/nrclinonc.2016.58. Epub 2016 May 4.
9
Association of Acute Interstitial Nephritis With Programmed Cell Death 1 Inhibitor Therapy in Lung Cancer Patients.肺癌患者程序性细胞死亡蛋白 1 抑制剂治疗与急性间质性肾炎的相关性。
Am J Kidney Dis. 2016 Aug;68(2):287-291. doi: 10.1053/j.ajkd.2016.02.057. Epub 2016 Apr 22.
10
Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.PD-1通路抑制剂纳武单抗在一名患有恶性肿瘤的肾移植患者中的应用。
Am J Transplant. 2016 Aug;16(8):2496-7. doi: 10.1111/ajt.13786. Epub 2016 Apr 21.
Zotero 插件